Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 10, 2020 06:30 ET | Source: ProMIS Neurosciences Inc.

ProMIS Neurosciences to Participate in H.C. Wainwright & Co. 22nd Annual Investment Conference

TORONTO and CAMBRIDGE, Mass., Sept. 10, 2020 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody...
August 13, 2020 06:30 ET | Source: ProMIS Neurosciences Inc.

ProMIS Neurosciences Announces Second Quarter 2020 Results

TORONTO and CAMBRIDGE, Mass., Aug. 13, 2020 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS or the Company”), a biotechnology company focused on the discovery and...
July 29, 2020 13:17 ET | Source: ProMIS Neurosciences Inc.

ProMIS Neurosciences Announces Results of Annual Meeting of Shareholders

TORONTO and CAMBRIDGE, Mass., July 29, 2020 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (the "Corporation") (TSX: PMN; OTCQB: ARFXF), a biotechnology company focused on the discovery and...
July 09, 2020 06:30 ET | Source: ProMIS Neurosciences Inc.

ProMIS Neurosciences and BC Neuroimmunology announce revenue-sharing joint venture agreement to develop and offer blood-based diagnostic tests for Alzheimer’s disease

TORONTO and CAMBRIDGE, Mass., July 09, 2020 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a company with unique, core technology to predict novel targets (peptide...
June 24, 2020 06:30 ET | Source: ProMIS Neurosciences Inc.

ProMIS Neurosciences announces adjournment and change of location of annual meeting of shareholders

TORONTO and CAMBRIDGE, Mass., June 24, 2020 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody...
June 17, 2020 06:30 ET | Source: ProMIS Neurosciences Inc.

ProMIS Neurosciences and collaborator BC Neuroimmunology announce significant progress on development of highly accurate antibody test for COVID-19

TORONTO and CAMBRIDGE, Mass., June 17, 2020 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a company with unique, core technology to predict novel targets on the molecular...
May 28, 2020 06:30 ET | Source: ProMIS Neurosciences Inc.

ProMIS Neurosciences and collaborative team receive Supercluster Award supporting avoidance of future pandemics by new strains of the COVID-19 virus

TORONTO and CAMBRIDGE, Mass., May 28, 2020 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a company with unique core technology to predict novel targets on the molecular...
May 20, 2020 06:30 ET | Source: ProMIS Neurosciences Inc.

ProMIS Neurosciences Chairman’s Update details new programs from expanded use of novel technology platform

TORONTO and CAMBRIDGE, Mass., May 20, 2020 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody...
May 19, 2020 06:30 ET | Source: ProMIS Neurosciences Inc.

ProMIS Neurosciences and BC Neuroimmunology expand collaboration to develop and commercialize proprietary diagnostic assays

TORONTO and CAMBRIDGE, Mass., May 19, 2020 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a company with unique, core technology to predict novel targets on the molecular...
May 13, 2020 06:30 ET | Source: ProMIS Neurosciences Inc.

ProMIS Neurosciences Announces First Quarter 2020 Results

TORONTO and CAMBRIDGE, Mass., May 13, 2020 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS or the Company”), a biotechnology company focused on the discovery and...